FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have obesity
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the first medication for certain patients with the condition.
Weight Loss Drug Zepbound Could Treat Sleep Apnea Without a CPAP or Surgery
GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly's weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
This Popular Weight Loss Drug Can Now Be Used To Treat Sleep Apnea
Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's division of pulmonology, allergy, and critical care.
IBX will no longer cover drugs like Ozempic when they are prescribed solely for weight loss
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
Health on MSN12d
Study Finds Nearly Half of People on Obesity Drugs Drink Less—But Do Scientists Know Why?
New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...
The Washington Post1mon
Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr.
The American Academy of Family Physicians, the American Medical Association and other medical groups have called for expanding insurance coverage for anti-obesity medication, with physicians ...
News Medical21d
Anti-obesity medications could help treat alcohol use disorders
Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.
Federal Times on MSN6d
What federal employees need to know about 2025 benefits changes
With major changes coming to the Federal Employee Health Benefits (FEHB) plan, employees and retirees need to pay extra ...
WFAE23d
Dizzy after one drink? Social drinkers on obesity drugs lose the taste for alcohol
"The main finding is that approximately 50% of patients who consumed alcohol at baseline reported decreased alcohol use after ...
FoodNavigator14d
Could GLP-1 drugs curb alcohol consumption?
Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...
Gizmodo1mon
Losing Weight With Ozempic Might Also Lighten Your Bar Tab, Study Finds
and looked at changes in alcohol use before and after initiation of an anti-obesity medication, whereas other work has not looked at pre- and post-changes and have primarily looked at those with ...
Sandoz Boss Warns There’s a Climate Cost of Obesity Wonder Drugs
Richard Saynor sees opportunity in copying cutting-edge medication and extols the merits of being boring. Richard Saynor ...